Ryan Cassaday, MD

CAR T-cell therapy can serve as a frontline treatment option for patients with high risk B-cell lymphomas with CD-19 CAR T-cells, according to a presentation from ASH Annual Meeting and Exposition.

Ryan Cassaday, MD, associate professor at University of Washington & Fred Hutchinson Cancer Research Center and attending physician at Seattle Cancer Care Alliance, discussed emerging strategies and developments in HIV malignancies, CD-22 targeted CAR T-cells and other presentations at the ASH Annual Meeting and Exposition.

Ryan Cassaday, MD, associate professor of hematology at University of Washington, discussed new platforms for cellular immunotherapy and the Devillier presentation of natural killer (NK) cells in a therapeutic setting presented at the ASH Annual Meeting and Exposition.